Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Total Current Liabilities: ¥554 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
91 GF Score
Price ¥57.60
GF Value ¥48.16
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co Total Current Liabilities?

Chengdu Easton Biopharmaceuticals Co SHSE:688513 +5.44% 91 Total Current Liabilities is ¥554 Mil as of Mar. 2026. GuruFocus rates SHSE:688513 with a GF Score™ of 91/100 and a GF Value™ of ¥48.16 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Chengdu Easton Biopharmaceuticals Co's total current liabilities for the quarter that ended in Mar. 2026 was ¥554

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Chengdu Easton Biopharmaceuticals Co Total Current Liabilities Related Terms

Chengdu Easton Biopharmaceuticals Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Chengdu Easton Biopharmaceuticals Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Easton Biopharmaceuticals Co Total Current Liabilities Chart

Chengdu Easton Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 432.46 529.39 661.09 596.32 618.70

Chengdu Easton Biopharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 593.43 581.82 593.27 618.70 553.64
SHSE:688513
91GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Easton Biopharmaceuticals Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Chengdu Easton Biopharmaceuticals Co's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=475.24+115.114
+Other Current Liabilities+Current Deferred Liabilities
=28.343+0
=619

Chengdu Easton Biopharmaceuticals Co's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=470.453+49.779
+Other Current Liabilities+Current Deferred Liabilities
=33.406+0
=554

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of ¥554 Mil mean?
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Total Current Liabilities of ¥554 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Chengdu Easton Biopharmaceuticals Co and its competitors.
Is Chengdu Easton Biopharmaceuticals Co's Total Current Liabilities too high?
Chengdu Easton Biopharmaceuticals Co's current Total Current Liabilities is ¥554 Mil. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Total Current Liabilities compare to VRTX and REGN?
Chengdu Easton Biopharmaceuticals Co's Total Current Liabilities of ¥554 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Total Current Liabilities is ¥554 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥48.16, compared to a current price of ¥57.60 — trading 19.6% above its estimated fair value. The current Total Current Liabilities is ¥554 Mil. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Total Current Liabilities is ¥554 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued. The current stock price of ¥57.60 is trading 19.6% above its estimated GF Value™ of ¥48.16. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.

Key valuation signals for SHSE:688513:

  • Total Current Liabilities: ¥554 Mil
  • GF Value™: ¥48.16 vs. price of ¥57.60 (19.6% above fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
91GF Score

Get the complete analysis for SHSE:688513

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥57.60
Price
¥48.16
GF Value